Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The
increasing number of patients with glaucoma is leading the retinal vein occlusion market
offering a huge growth opportunity to the market players. Moreover, the growing number of
patients affected with lymphoma and multiple myeloma is also fueling the growth of the
global retinal vein occlusion market.
The Global Retinal Vein Occlusion Market is expected to grow at a CAGR of 11.2%
during the forecast period 2017-2023.
According to the Centers for Disease Control and Prevention, in 2014, around 47,135 people
were diagnosed with leukemia and out of which 23,564 people died from the disease.
According to the American Cancer Society, around 4% of all cancers in the United States is
lymphoma, additionally, it is estimated that in 2018, about 74,680 people including both
adults and children will be diagnosed with lymphoma and around 19,910 people will die
from this. According to the American Cancer Society, the risk of acquiring multiple myeloma
in the United States is 1 in 143 that is 0.7%, additionally, it is estimated that in 2018,
around 30,770 new cases are likely to be diagnosed and the estimated death toll would be
around 12,770.
Segmentation
The Global Retinal Vein Occlusion Market is segmented on the basis of type, condition,
diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch
retinal artery occlusion and central retinal vein occlusion. On the basis of the condition, it is
segmented into non-ischemic and ischemic. Based on the diagnosis, it is segmented into
optical coherence tomography (OCT), fundoscopic examination, fluorescein angiography,
and others. On the basis of treatment, it is segmented into antivascular endothelial growth
factor, corticosteroid drugs, laser retinal photocoagulation, and others. On the basis of the
end users, it is segmented into hospitals and clinics, research & academics centers, and
others.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/5377 .
Major Players in the Retinal Vein Occlusion Market
Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers,
GlaxoSmithKline Plc, IRIDEX Corporation, Novartis, Quantel Medical Inc, Topcon Medical
Systems, Inc., ZEISS, Lumenis, Sanofi Aventis, Valeant Pharmaceuticals, Alimera Sciences,
Fovea Pharmaceuticals SA, Icon Biosciences, Suzuken Co.Ltd, Genentech, Inc., Ranbaxy
Pharmaceuticals, Johnson & Johnson Services, Inc, Teva Pharmaceutical, Pfizer Inc.,
Astrazeneca, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB and others.
The Global Retinal Vein Occlusion Market consists of four regions: the Americas, Europe,
Asia Pacific, and the Middle East & Africa.
The Americas dominate the global retinal vein occlusion market owing to the increasing
prevalence of eye diseases. Additionally, high healthcare spending, well-developed
technology, and increasing geriatric population will fuel the growth of the market.
The Americas market for retinal vein occlusion is divided into North America and South
America. North America holds the major share in the market whereas, South America is
showing the fastest growth owing to the presence of a huge opportunity for the
development of the market in the region.
The Europe retinal vein occlusion market comprises of Eastern Europe and Western Europe.
Western Europe comprises of countries such as Germany, the U.K, France, Italy, and Spain.
Europe accounts for the second largest market for the global retinal vein occlusion owing to
increasing support from the government, the presence of huge geriatric population, and
high healthcare spending. Also, many European countries are trying to encourage the
manufacturers for research & development for the introduction of advanced devices. In
addition to this, increasing awareness and development in the healthcare infrastructure has
provided a push to the growth of the market.
Asia Pacific is the fastest growing market for the global retinal vascular or vein occlusion.
Presence of huge patient population, rapid development in technology and presence of a